Finoriq research workspace
Royalty Pharma plc (RPRX) Historical Metrics
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in. Review RPRX valuation ratios, fundamentals, and filing metrics on Finoriq.
Company Snapshot
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.
- Company
- Royalty Pharma plc (RPRX)
- Ticker
- RPRX
- Market Cap
- $33.2B
- Latest Price
- $57.58
- Industry
- Biotech & Pharma
Royalty Pharma plc (RPRX) Current Valuation Metrics
Static valuation preview for Royalty Pharma plc (RPRX). Market data retrieved 2026-07-08. Filing currency USD.
| Metric | Value | Source |
|---|---|---|
| P/EMarket cap divided by latest TTM net income. | 43.5x | Net Income | TTM FY 2025 |
| P/SMarket cap divided by latest TTM revenue. | 14.1x | Revenue | TTM FY 2025 |
| P/Operating Cash FlowMarket cap divided by latest TTM operating cash flow. | 13.5x | Operating Cash Flow | TTM FY 2025 |
| Earnings YieldLatest TTM net income divided by market cap. | 2.3% | Net Income | TTM FY 2025 |
| Operating Cash Flow YieldLatest TTM operating cash flow divided by market cap. | 7.4% | Operating Cash Flow | TTM FY 2025 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.